Neurologic manifestations of nonhospitalized patients with COVID‐19 in Wuhan, China

Notably, our results revealed that neurologic manifestations were common in nonhospitalized patients in Wuhan (total, 77.8%; CNS, 46.7%; PNS, 69.3%), and the rates were higher than previously reported in hospitalized patients from the same area (36.4% had neurologic manifestations), probably as a result of our meticulous recording and long-term following-up revealing more details that were preciously overlooked. TABLE 1 Demographics and clinical characteristics of non-hospitalized COVID-19 patients in Wuhan No. (%) Characteristic Total Pneumonia Nonpneumonia P value No. of patients 153 96 (62.7) 57 (37.3) N.A. Age, mean [range], years 44.9 [18-79] 44.2 [18-79] 42.3 [28-69] 1 Male 56 (36.6) 40 (41.7) 16 (28.1) .11 Fever 80 (52.3) 77 (80.2) 3 (5.4) 5.04 × 10−21 Dry cough 77 (50.3) 66 (68.8) 11 (19.3) 2.37 × 10−9 Shortness of breath 36 (23.5) 35 (36.5) 1 (1.8) 9.78 × 10−8 CT findings 116 (75.8) 96 (100) 20 (35.1) 2.82 × 10−21 Anorexia 17 (11.1) 11 (11.5) 6 (0.5) 1 Diarrhea 42 (27.5) 27 (28.1) 15 (26.3) .85 Pharyngalgia 29 (19) 19 (19.8) 10 (17.5) .83 Nausea 9 (5.9) 2 (2.1) 7 (12.3) .01 Fatigue 78 (51) 51 (53.1) 27 (47.4) .51 Chest pain 32 (20.9) 23 (24) 9 (15.8) .3 Chest tightness 45 (29.4) 33 (34.4) 12 (21.1) .1 Palpitation 53 (34.6) 37 (38.5) 16 (28.1) .29 Nervous system symptoms Any 119 (77.8) 71 (74.0) 48 (84.2) .16 CNS 71 (46.4) 44 (45.8) 27 (47.4) .87 Headache 48 (31.4) 33 (34.4) 15 (26.3) .37 Dizziness 18 (11.8) 12 (12.5) 6 (10.5) .8 PNS 106 (69.3) 61 (63.5) 45 (78.9) .05 Impaired taste and smell 28 (18.3) 16 (16.7) 12 (21.1) .52 Impaired vision 5 (3.3) 0 (0) 5 (8.8) .01 Nerve pain 86 (56.2) 54 (56.3) 32 (56.1) 1 Arthralgia 6 (3.9) 3 (3.1) 3 (5.3) .67 Tingling and numbness 17 (11.1) 4 (4.2) 13 (22.8) 8.0 × 10−4 Excessive sweating 41 (26.8) 28 (29.2) 13 (22.8) .45 Muscle weakness 10 (6.5) 4 (4.2) 6 (10.5) .18 Disease duration 0-1 week 9 (5.9) 5 (5.2) 4 (7) .73 1–2 weeks 34 (22.2) 25 (26) 9 (15.8) .16 2–3 weeks 44 (28.8) 39 (40.6) 5 (8.8) 1.56 × 10−5 3–4 weeks 24 (15.7) 13 (13.5) 11 (19.3) .36 4–8 weeks 25 (16.3) 14 (14.6) 11 (19.3) .5 >8 weeks 17 (11.1) 0 (0) 17 (29.8) 9.06 × 10−9 IgM/IgG serology No. of patients 77 49 28 N.A. IgM (−) IgG (+) 31 (40.3) 27 (55.1) 4 (14.3) 5.91 × 10−4 IgM (+) IgG (+) 15 (19.5) 10 (20.4) 5 (17.9) 1 IgM (+) IgG (−) 10 (13) 2 (4.1) 8 (28.6) .004 IgM (−) IgG (−) 21 (27.3) 10 (20.4) 11 (39.3) .11 Moreover, as shown in Table , nonpneumonia cases, compared to pneumonia cases, were associated with prolonged disease courses (>8 we